On the basis of our earlier findings indicating robust apoptosis induction in cancer cells by CFM-4 [15], and the fact that Cisplatin treatments failed to alter expression of p21Rac1 or podoplanin in MPM cells (figures 5, 8) coupled with our data demonstrating inhibition of a diverse metastasis signaling by CFM-4 would argue for its pleiotropic anti-cancer properties, and collectively indicate for potential of CFM-4 and/or its futuristic analogs as suitable anti-MPM agents. The gene discussed is RAC1; the disease is cancer.